The FDA’s top drug regulator was placed on administrative leave after exposing a secretive fast-track approval process that bypasses decades-old safety protocols, raising alarms about potential corruption in America’s drug oversight system.
Story Highlights
- Dr. George Tidmarsh, head of the FDA’s drug evaluation center, was placed on leave after challenging questionable approval processes.
- New fast-track system gives a single official control over drug approvals, circumventing scientific debate.
- Tidmarsh claims retaliation for opposing regulatory changes that abandon the FDA’s historical safety standards.
- Secretary Kennedy promises transparency amid accusations of a toxic work environment.
Top FDA Official Challenges Dangerous New Approval System
Dr. George Tidmarsh, who leads the FDA’s Center for Drug Evaluation and Research, was placed on administrative leave after raising serious concerns about a new regulatory process.
The system uses a tumor board-style review to fast-track drug approvals for “companies aligned with critical U.S. national health priorities.” Tidmarsh warned that this arrangement fundamentally differs from decades of established FDA protocols and concentrates dangerous power in a single official’s hands.
The Food and Drug Administration’s top drug regulator has resigned after being accused of soliciting a bribe and tanking a company’s stock as part of an alleged revenge plot against a former colleague. https://t.co/tm2esMU5wu
— The Daily Beast (@thedailybeast) November 3, 2025
Retaliation Claims Surface After Whistleblowing
Tidmarsh denies allegations of personal misconduct and claims his suspension represents retaliation for speaking out against Vinay Prasad, the FDA’s chief medical and scientific officer.
According to Tidmarsh, the new approval process “circumvents rigorous scientific debate and puts Vinay Prasad in charge of every drug approval.” This concentration of authority undermines the collaborative scientific review process that has protected Americans from dangerous medications for generations.
Emily Hilliard, an HHS spokeswoman, stated Tidmarsh was placed on leave “after the Office of the General Counsel and the Office of the Inspector General were notified of serious concerns about his personal conduct.” STAT News reported accusations that Tidmarsh used regulatory authority to harm a former business associate, allegations he firmly denies.
Toxic Environment Threatens Drug Safety Oversight
Tidmarsh describes the current FDA environment as “toxic” and harmful to American patients. He told ABC News he would “resign from a place as toxic as the current environment” and called the situation “bad for the American people.” His willingness to sacrifice his career to expose these issues demonstrates the severity of problems within the agency responsible for protecting public health.
Secretary Kennedy responded through his spokeswoman, Hilliard, stating that he “expects the highest ethical standards from all individuals serving under his leadership and remains committed to full transparency.”
However, HHS declined to address Tidmarsh’s specific retaliation claims, raising questions about whether genuine reform efforts will address the systemic issues he exposed.
